Skip to main content
. 2020 Jul 27;4:PO.20.00098. doi: 10.1200/PO.20.00098

FIG 3.

FIG 3.

Crizotinib progression patterns. An alluvial plot of patients with MET exon 14–altered non–small-cell lung cancer (NSCLC) including 54 patients who were treated with crizotinib is shown. Patterns of disease progression including intracranial-only progression, intracranial and extracranial progression, and extracranial-only progression are depicted.